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Abstract. The GPI-anchored urokinase plasminogen 
activator receptor (uPAR) does not internalize free 
urokinase (uPA). On the contrary, uPAR-bound com- 
plexes of uPA with its serpin inhibitors PAI-1 (plasmi- 
nogen activator inhibitor type-l) or PN-1 (protease 
nexin-1) are readily internalized in several cell types. 
Here we address the question whether uPAR is inter- 
nalized as well upon binding of uPA-serpin complexes. 
Both LB6 clone 19 cells, a mouse cell line transfected 
with the human uPAR cDNA, and the human U937 
monocytic cell line, express in addition to uPAR also 
the endocytic et2-macroglobulin receptor/low density li- 
poprotein receptor-related protein (LRP/a2-MR) 
which is required to internalize uPAR-bound uPA- 
PAI-1 and uPA-PN-1 complexes. Downregulation of 
cell surface uPAR molecules in U937 cells was de- 
tected by cytofluorimetric analysis after uPA-PAI-1 
and uPA-PN-1 incubation for 30 min at 37°C; this effect 
was blocked by preincubation with the ligand of LRP/ 
aE-MR, RAP (LRP/a2-MR-associated protein), known 
to block the binding of the uPA complexes to LRP/et  E- 
MR. Downregulation correlated in time with the intra- 
cellular appearance of uPAR as assessed by  confocal 
microscopy and immuno-electron microscopy. After 30 
min incubation with uPA-PAI-1 or uPA-PN-1 (but not 
with free uPA), confocal microscopy showed that 
uPAR staining in permeabilized LB6 clone 19 cells 
moved from a mostly surface associated to a largely 
perinuclear position. This effect was inhibited by the 
LRP/a2-MR RAP. Perinuclear uPAR did not represent 
newly synthesized nor a preexisting intracellular pool 
of uPAR, since this fluorescence pattern was not modi- 
fied by treatment with the protein synthesis inhibitor 
cycloheximide, and since in LB6 clone 19 cells all of 
uPAR was expressed on the cell surface. Immuno-elec- 
tron microscopy confirmed the plasma membrane to in- 
tracellular translocation of uPAR, and its dependence 
on LRP/ot2-MR in LB6 clone 19 cells only after binding 
to the uPA-PAI-1 complex. After 30 min incubation at 
37°C with uPA-PAI-1, 93 % of the specific immunogold 
particles were present in cytoplasmic vacuoles vs 17.6% 
in the case of DFP-uPA. We conclude therefore that in 
the process of uPA-serpin internalization, uPAR itself 
is internalized, and that internalization requires the 
LRP/a2-MR. 
I 
N processes like cellular invasion and cell migration ex- 
tracellular proteolytic activities  are  localized  at the 
moving edges of the cells. Urokinase plasminogen ac- 
tivator (uPA)  t is a cell surface protease that regulates cell 
migration  and  invasiveness  either  through  a  focal  and 
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1.  Abbreviations  used  in  this paper:  ATF,  amino-terminal fragment of 
uPA; GPI, glycosyl-phosphatidylinositol;  LRP/a2-MR, a2-macroglobulin 
receptor/low density lipoprotein receptor-related protein; PAl-l, plasmi- 
nogen activator inhibitor type-l; PN-1, protease-nexin 1; pro-uPA, pro- 
urokinase; RAP,  a2-macroglobulin receptor/low density lipoprotein re- 
transient  activation of plasminogen, hepatocyte growth 
factor, and TGF-[31 or through a direct effect on mitogen- 
esis, cell adhesion, and chemotaxis (for review see Fazioli 
and Blasi, 1994). The cell surface association  of uPA de- 
pends on the high affinity  interaction with a specific recep- 
tor (uPAR), via its growth factor domain (Vassalli et al., 
1985; Stoppelli  et al., 1985; Appella et al., 1987). The im- 
portance of uPA and uPAR in tumor invasion  is under- 
lined by the possibility to block basement membrane deg- 
radation, cancer cell invasion, and experimental metastasis 
ceptor-associated protein; uPA,  urokinase type plasminogen activator; 
DFP-uPA,  diisopropyl-fluorophosphate-inhibited uPA;  uPAR,  uroki- 
nase-type plasminogen activator receptor. 
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ization  (Bergman et al.,  1986;  Ossowski and Reich,  1983; 
Hearing et al., 1988;  Ossowski, 1988; Ossowski et al., 1991; 
Quax et al.,  1991; Crowley et al.,  1993; Kook et al., 1994; 
Kobayashi et al., 1994). The activity of uPA is controlled 
by specific endogenous inhibitors (PAI-1, PAI-2, and PN-1) 
belonging  to  the  superfamily  of serpins  (serine  protease 
inhibitors) (Huber and Carrell, 1989; Potempa et al., 1994), 
which  can react  with  uPAR-bound  uPA  and  inhibit  cell 
surface uPA enzymatic activity (Cubellis et al., 1989; Kirch- 
heimer and Remold, 1989; Ellis et al.,  1989; Estreicher et 
al., 1990). 
When active uPA is bound to the receptor, it is not in- 
ternalized  but remains  at the cell surface (Vassalli  et al., 
1985; Stoppelli et al., 1985; Cubellis et al.,  1986; Stoppelli 
et al., 1986). When, however, receptor-bound uPA is com- 
plexed to PAI-1, PAI-2, or PN-1, the complex is internal- 
ized  and  degraded  (Cubellis  et  al.,  1990;  Jensen  et  al., 
1990; Estreicher et al.,  1990; Conese et al.,  1994). Binding 
to uPAR is required for internalization and degradation of 
uPA-serpin  complex  (Olson  et  al.,  1992;  Nykjaer  et  al., 
1992;  Conese et al.,  1994). However, it has been recently 
shown that  a  trans-membrane receptor  belonging  to  the 
LDL-receptor family, namely the et2-macroglobulin recep- 
tor/low density lipoprotein receptor-related protein (LRP/ 
et2-MR  ) (or the epithelial glycoprotein-330, gp330, in kid- 
ney)  is also required for uPA:serpins internalization  and 
degradation (Nykj~er et al., 1992; Herz et al., 1992; Orth et 
al., 1992; Moestrup et al., 1993a; Li et al., 1994). 
LRP/a2-MR is a multiligand receptor that binds a2-mac- 
roglobulin:proteinase  complexes  (Moestrup  et al.,  1990), 
tissue-plasminogen  activator (tPA)  and tPA-PAI-1  com- 
plexes  (Orth  et  al.,  1992),  uPA-PAI-1  and  uPA-PN-1 
complexes (Nykj~er et al.,  1992; Conese et al.,  1994), pro- 
uPA (Kounnas et al., 1993; Nykj~er et al., 1994a), apolipro- 
tein E-enriched  13-migrating  very low density lipoprotein 
(Kowal  et  al.,  1990),  lipoprotein  lipase  (Beisigel  et  al., 
1991;  Nykj~er  et  al.,  1994b),  lactoferrin  (Willnow  et  al., 
1992), Pseudornonas aeruginosa exotoxin A  (Kounnas  et 
al.,  1992), the plant  type I  ribosome-inactivating  protein 
saporin (SAP) and its conjugate with uPA (Conese et al., 
1995), and a 39-40-kD receptor-associated protein (RAP) 
(Jensen et al.,  1989; Ashcom et al., 1990; Strickland et al., 
1991). uPA-serpin degradation in various cell types can be 
inhibited by RAP and by antibodies against the LRP/a2- 
MR  (Nykj~er et al.,  1992; Willnow et al., 1992; Herz et al., 
1992; Kounnas et al.,  1993; Conese et al., 1994). The uPA- 
PAL1 complex binds to LRP/et2-MR  through  sites local- 
ized in PAI-1, as well as in both the serine protease do- 
main and the A-chain of uPA, indicating the involvement 
of several independent  binding contacts with LRP/et2-MR 
(Nykj~er et al., 1994a). 
The various steps in uPA-serpin internalization  and deg- 
radation  are still poorly understood, uPA-PAI-1 internal- 
ization  and  lysosomal  accumulation  can  be followed by 
immunofluorescence  and by electron microscopy (Jensen 
et al.,  1990; Olson et al.,  1992), and it is known that LRP/ 
ere-MR is itself internalized  (Moestrup et al.,  1990;  Hop- 
kins et al., 1994). However, whether uPAR is also internal- 
ized along with the uPA-serpin and LRP/et2-MR is still un- 
known.  In  this  paper  we  directly  show  that  binding  of 
uPA-serpins to the cells induces internalization  of uPAR. 
Materials and Methods 
Reagents 
Two chain uPA was obtained from Lepetit SpA, courtesy of Dr. M. L. 
Nolli, and recombinant pro-uPA from Dr. Paolo Sarmientos (Primm, Mi- 
lano).  DFP-uPA (uPA inhibited with diisopropyl-fluorophosphate) was 
prepared as previously described (Nykj~er et al., 1990). Anti-uPAR mono- 
clonal antibody R2 was purified on a protein G Sepharose column using a 
commercial kit  (mAbTrap  TM G,  Pharmacia LKB, Sweden)  from hybri- 
doma cell culture supernatant and was donated by Drs. E. R~nne and G, 
HCyer-Hansen (Finsen Laboratory, Rigshospitalet, Copenhagen) (RCnne 
et al., 1991). Recombinant active PAI-1 (Sherman et al., 1992) and recom- 
binant PN-1  (PN-1)  were  generously donated  by  Dr.  David  Ginsburg 
(Howard Hughes Medical Institute, Ann Arbor, MI) and Dr. Randy Scott 
(Incyte Co., Palo Alto, CA), respectively. Recombinant 39 kD RAP and 
rabbit antiserum raised against a recombinant a-chain fragment of LRP! 
a2-MR (amino acids 2500-2922) have been described before (Nykj~er  et 
al., 1992,  1994a).  Purified LRP/ct2-MR and gp330 were prepared as de- 
scribed  previously  (Moestrup  and  Gliemann,  1991;  Moestrup  et  al., 
1993a).  Benzamidine Sepharose 6B was from Pharmacia LKB Biotech- 
nology (Piscataway,  NJ);  dimethyl-diphenylpolysiloxane and cyclohexi- 
mide were from Sigma Chem. Co (St.  Louis, MO). The cross-linking re- 
agent  disuccinimidyl-suberate  was  obtained  from  Pierce  Chem.  Co. 
(Rockford, IL). Phosphatidylinositol-specific  phospholipase C (PI-PLC) from 
B. cereus was from Boehringer Mannheim Gmbh (Penzberg, Germany). 
Cell Lines and Cell Cultures 
Growth conditions for the human monocyte-like U937 cells and for the 
murine LB6 clone 19 cells, a mouse cell line expressing the human uPA- 
receptor, have been previously described  (Picone et al., 1989; Roldan et 
al., 1990). 
The assays for ligand binding, internalization, and degradation for both 
U937 and LB6 clone 19 cells have been previously described (Olson et al., 
1992; Conese et al., 1994). 
Iodinations 
Iodination of uPA, ATF, and RAP with Iodogen (Pierce Chem. Co.) has 
been described (Behrendt etal., 1990; Nykj~er et al., 1992). Specific activi- 
ties of the proteins ranged between 2.5 and 7,5 ×  105 cpm/pmol. Enzymat- 
ically active iodinated uPA was purified by affinity chromatography on 
benzamidine Sepharose 6B (Holmberg et al., 1976). 
Formation of uPA-serpin Complexes 
uPA-PAI-1 complexes were formed combining benzamidine-Sepharose 
purified 125I- or unlabeled uPA and a  50-fold molar excess of PAI-1 at 
room temperature for 2 h. The inhibitor:uPA ratio was experimentally de- 
termined to convert over 90% of the uPA to the complex form as deter- 
mined by SDS-PAGE analysis (not shown), uPA-PN-1 was formed under 
identical conditions, as previously described (Conese et al., 1994). 
Cytofluorimetric Analysis 
Acid washed-U937 cells (106) were incubated with 1 nM uPA, uPA-PAI-1, 
or uPA-PN-1 complexes for 2 h at 4°C eventually followed by 30 min at 
37°C. Cells were washed twice with PBS, and incubated in 0.1 ml PBS and 
30 ~g/ml of the uPAR-specific monoclonal antibody (R~nne et al., 1991) 
R2 for 30 rain at 4°C. Cells were then washed twice with PBS and resus- 
pended in PBS containing a  1:50 dilution of fluorescein-conjugated anti- 
body against mouse IgG (Dakopatts, Copenhagen,  Denmark). After 30 
min at 4°C, cells were washed twice and analyzed by flow cytofluorimetry 
with a FACScan apparatus (Becton Dickinson, San Jose, CA). To express 
the data, the cell number was plotted against the log of the mean fluores- 
cence intensity. About 5,000 cells were measured at each determination. 
The negative control was obtained incubating the cells in the absence of 
the primary antibody. 
Confocal Immunofluorescence Microscopy 
For confocal microscopy, 0.2 x  106 LB6 clone 19 cells were plated onto 24- 
well Costar plates containing 1.4 cm  2 round glass coverslips. Coverslip- 
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paraformaldehyde) in PBS, pH 7.6 containing 2% sucrose for 10 min at 
4°C. Coverslips were soaked, after fixation, for 1 min in ice-cold Hepes- 
Triton X-100 buffer (20 mM Hepes, pH 7.4, 3 mM MgCI2 and 0.5% Triton 
X-100) to obtain permeabilization. Monoclonal anti-uPAR antibody R2 
was used at  15 ixg/mL in TBS-0.2% BSA. As secondary antibody, we used 
a goat-anti-mouse rhodamine-conjugated IgG F(ab') 2 fragment (Protos 
Immunoresearch, San Francisco, CA) diluted  1:200  in TBS-0.2%  BSA. 
Coverslips were then mounted in 20% Mowiol 4-88 in TBS (HOECHST 
AG, Frankfurt, Germany). Observations were carried out on a  Sarastro 
2000  confocal laser  scanning system (Molecular  Dynamics, Sunnyvale, 
CA) equipped with a two wavelength Argon ion laser (488 and 514 nm) 
and with a Zeiss Axioskop fluorescence microscope. The objectives used 
were  a  plan-apochromatic  63×/1.4  and  a  plan-apochromatic  100x/1.3 
(Carl Zeiss). Optical sections of 0.29 I~m thickness were saved as 512  x 
512 pixel images at 8 bit resolution (256 gray levels), and then processed 
as TIFF files on a Silicon graphics workstation. Images were printed on 
photographic quality paper  using a  sublimation ink printer  (Mitsubishi 
Electric Corporation, Tokyo, Japan). 
Electron Microscopy 
LB6 clone 19 cells (5  x  106) were incubated under four different condi- 
tions: (a) for 2 h with 100 nM uPA-PAI-1 at 0°C, washed, and then fixed; 
(b) preincubated for 2  h  with  100 nM uPA-PAI-1  at 0°C, washed and 
chased for 30 min at 37°C, fixed; (c) preincubated for 30 min at 0°C with 
400 nM RAP, and then for 2 h with 100 nM uPA-PAI-1 at 0°C together 
with RAP, washed and chased in the presence of 400 nM RAP for 30 min 
at 37°C and finally fixed; (d) preincubated for 2 h with 100 nM DFP-uPA 
at 0°C, chased for 30 min at 37°C, and then fixed. In all cases, incubation 
mixtures contained 5 mM methylamine. The cells were fixed with 0.1% 
glutaraldehyde and 2% formaldehyde in 0.1 M sodium cacodylate buffer, 
pH 7.2, for 1 h and subsequently postfixed for up to 18 h in 2% formalde- 
hyde in the same buffer. The cells were then infiltrated with 2.3 M sucrose 
containing 2% formaldehyde for 30 min and frozen in liquid nitrogen. Ul- 
trathin cryosections, 70-90 p~m, were obtained with a  FCS Reichert U1- 
tracut S cryoultramicrotome at about -100°C and collected on 300 mesh 
Ni grids. The sections were  incubated overnight at 4°C with the mouse 
monoclonal anti-uPAR antibody R2, 1~40 ixg/ml or with a polyclonal af- 
finity-purified rabbit  anti-uPAR antibody  (2.5  ~g/ml) and subsequently 
with  10-nm  goat  anti-mouse-gold  or  goat  anti-rabbit-gold  (BioCell, 
Cardiff, UK) at 4°C for 2 h. The sections were finally contrasted with methyl 
cellulose containing 0.3% uranylacetate (Tokuyasu, 1978; Griffiths et al., 
1984)  and studied in a Philips EM208 or a Philips CM100 electron micro- 
scope. Controls, incubated with nonspecific monoclonal antibody, protein 
A  affinity purified rabbit immunoglobulin, preabsorbed polyclonal rabbit 
anti-uPAR immunoglobulin or without primary antibody showed no spe- 
cific labeling at all. 
The immunogold distribution over the cells, using the polyclonal affin- 
ity-purified rabbit anti-uPAR antibody, was determined quantitatively as 
follows. Approximately 25 electron micrographs were taken at random, 
but including as much cytoplasm and cell surface as possible from each of 
the four groups at a primary magnification of 15,500,  and then enlarged 
3x. Gold-particles were counted over the plasma membrane and over cy- 
toplasmic vacuoles. The cytoplasmic areas analyzed in the four groups, as 
determined by point counting, were essentially identical (311  p~m  2 for a, 
423 for b, 379 for c, and 420 for d).  The total number of gold particles 
counted was 8,149. The background labeling which was determined in the 
four groups by counting gold  particles  over  nuclei was extremely low, 
ranging from 0.2-0.4 gold particles/p.m  2. 
Release of uPAR by PI-PLC and Cross-Linking 
to 125  I-A TF 
LB6 clone 19 cells (0.2 x  106/well)  were incubated with serum-free me- 
dium  or  with  medium supplemented with  phosphatidylinositol-specific 
phospholipase C (PI-PLC) (10 U/ml) for 15 min at 37°C. At the end of the 
incubation, the supernatant was recovered and the pelleted cells were ex- 
tracted in lysis buffer (0.1  M Tris-C1, pH 8.1, 10 mM EDTA, 1% Triton 
X-100, and 1%  aprotinin). Cell extracts or supernatants were cleared at 
15,000 g for 10 min at 4°C and tested for uPAR by cross-linking to 125I-ATF 
(60,000 clam), using 1 mM disuccinimidyl suberate, as previously described 
(Behrendt et al., 1990). The samples were analyzed by SDS-PAGE (12%) 
gel electrophoresis (Laeramli,  1970)  under nonreducing conditions. The 
specificity of the 125I-ATF-uPAR conjugate was demonstrated by compe- 
tition with unlabeled free uPA. 
Ligand- and Immuno-Blotting Procedures 
For  ligand blotting,  purified  LRP/a2-MR or detergent phase separated 
membrane fractions were run in 4-16%  SDS-PAGE under nonreducing 
conditions, electroblotted  to  PVDF membranes (Immobilon, Millipore) 
and blocked for 2  h  at 20°C in binding buffer (140  mM NaCl,  10  mM 
Hepes, 2 mM CaC12, 1 mM MgCI2, pH 7.8) containing 2% defatted milk 
powder. The filters were then incubated for 16 h at 4°C in the presence of 
50 pM iodinated ligands in binding buffer supplemented with 0.5% BSA, 
washed three times, and autoradiographed for 12-18 h. 
Immuno-blotting with a rabbit-antiserum raised against a recombinant 
fragment of the c~-chain of LRP/~t2-MR, was performed as described pre- 
viously (Nykj~er et al., 1994a). 
Results 
LRP/a2-MR Dependence of the Internalization 
of the uPA-Serpin Complexes  in U937 and LB6 
Clone 19 Cells 
Efficient internalization of uPA-PAI-1  requires the par- 
ticipation  of  both  LRP/et2-MR  (Strickland  et  al.,  1991; 
Nykj~er et al., 1992; Herz et al.,  1992; Willnow et al., 1992; 
Moestrup  et  al.,  1993b;  Conese  et al.,  1994)  and  uPAR 
(Olson et al., 1992; Conese et al., 1994). We first tested for 
the presence of LRP/ctE-MR in LB6 clone 19 cells, a mu- 
rine cell line transfected with human uPAR cDNA (Roldan 
et al., 1990).  Triton X-114 extracts of LB6 clone 19 cells 
were phase  separated  and  analyzed for the  presence of 
LRP/ctE-MR and uPAR in both the water and the deter- 
gent phases. Purified LRP/a2-MR and gp330 were used as 
positive controls in the identification. Cell extracts in Tri- 
ton X-114 were phase separated and the two phases ana- 
lyzed, by ligand blotting procedures, for binding to  125I- 
uPA-PAI-1,125I-RAP and to anti-LRP/aE-MR antibodies. 
The following data (Fig. 1) show that LB6 clone 19 cells 
contain, in addition to uPAR, also LRP/a2-MR. In the wa- 
ter soluble extract, t25I-uPA-PAI-1 bound to a slowly mi- 
grating band comigrating with authentic LRP/a2-MR; how- 
ever, in the detergent-soluble extract, it bound to a different 
faster migrating band (first panel). The latter band corre- 
sponds to uPAR on the basis of comigration with authen- 
tic uPAR  (not shown)  and  several previously published 
criteria (Plough et al., 1991; Behrendt et al.,  1990; Conese 
et al.,  1994).  On the other hand, 125I-RAP bound only to 
the LRP/et2-MR band in the water-phase, and did not bind 
to any protein present in the detergent phase (Fig. 1, sec- 
ond panel).  The  binding  of  125I-uPA-PAI-1  to  LRP/ct2- 
MR-comigrating band in the water extract was competed 
for by unlabeled  RAP  (Fig.  1, fourth  panel),  supporting 
the identification of this band as LRP/a2-MR. Finally, the 
LRP/a2-MR band in the water phase was recognized by 
specific anti-LRP/a2-MR antibodies (third panel). We con- 
clude, therefore, that LB6 clone 19 cells contain, in addi- 
tion to uPAR, also LRP/ctz-MR. The presence of both these 
receptors on U937 ceils was previously reported (Conese 
et al., 1995). 
We next tested whether internalization and degradation 
of uPA-PAI-1 in LB6 clone 19 cells were also dependent 
on the LRP/a2-MR.  RAP and a  soluble LRP/et2-MR  , re- 
agents which interfere with the binding of all ligands  to 
cellular LRP/etE-MR  , did not inhibit binding of uPA, uPA- 
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Figure 1. Ligand blot analysis  shows that LB6 clone 19 cells con- 
tain LRP/a2-MR. 0.25 Ixg purified gp330 or LRP/c~2-MR and de- 
tergent (D) and water (W) phases from extracts in Triton X-114 
prepared from 5 x 10  6 LB6 clone 19 cells, were applied to 4-16% 
SDS-PAGE, electroblotted to PDVF membranes, blocked, and 
incubated for 16 h at 4°C with the reagents indicated at the bot- 
tom of each  lane  at  the  following concentrations: 50  pM  1251- 
uPA-PAI-1 in the absence or presence of 400 nM RAP; 50 pM 
125I-RAP  or  1:1,000 dilution  of LRP/et2-MR  antiserum.  After 
washing the membranes,  bound radioactivity was visualized  by 
autoradiography  while  anti-LRP/et2-MR  antibodies  were  de- 
tected by a peroxidase-coupled anti-rabbit antibody (see Materi- 
als and Methods). 
PAI-1 and uPA-PN-1 complexes to neither of the two cell 
lines  LB6 clone  19  and  U937  cells  (data  not  shown),  in 
agreement with published data (Nykj~er et al., 1992; Olson 
et al., 1992; Conese et al., 1994). However, internalization 
and degradation  of 125I-uPA-PAI-1 in LB6 clone 19 cells 
were inhibited  by these  two reagents.  As shown in Fig. 2 
A, the  amount of internalized  125I-uPA-PAI-1 was maxi- 
mal at 30 min of incubation and decreased thereafter.  On 
the contrary, degradation of 125I-uPA-PAI-1 reached satu- 
ration at about 60 min (Fig. 2 B). Both internalization and 
degradation  of  125I-uPA-PAI-1 were  strongly  decreased 
when the  experiment  was carried  out in  the  presence  of 
RAP or of the soluble LRP/a2-MR. The same results were 
obtained  with  U937  cells  and  for  uPA-PN-1  complexes 
(not  shown).  The  high  background  of internalization  at 
time zero is a phenomenon regularly observed even in the 
presence of noninternalized  ligands of uPAR (Cubellis  et 
al., 1990), and is not accompanied by degradation (which is 
in fact null at this time, Fig. 2 B), thus probably represent- 
ing an artifact  due  to the temperature  shift  (see  also an- 
other experiment, in Fig. 6). The overall results of this ex- 
periment are in line with previous data on other cell lines 
and  with  the  hypothesis  that  the  uPA-serpin  complexes 
first bind to cell surface uPAR and subsequently are trans- 
ported  intracellularly  via the LRP/c~2-MR (Nykj~er et  al., 
1992; Conese et al., 1994). 
From these data and from those in the literature (Nykj~er 
et al., 1992; Herz et al., 1992; Kounnas et al., 1993; Conese 
et al., 1994), we conclude that in U937 and LB6 clone 19 cells 
uPA-serpin  internalization  occurs  in  three  steps:  a  first 
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Figure 2.  RAP and soluble LRP/ct2-MR  inhibit  1251-uPA-PAI-1 
internalization and degradation in LB6 clone 19 cells. LB6 clone 
19 (0.2  x  106/well) were incubated with 100,000 cpm 125I-uPA- 
PAI-1 (1 nM, 9,000 cpm/ng) for 2 h at 4°C, and then transferred at 
37°C for various time intervals in the absence (open circles) or in 
the presence of 200 nM RAP (closed circles) or 200 nM soluble 
LRP/ot2-MR (closed  squares). Internalized ligand (i.e., radioactiv- 
ity remaining in the cell  pellet after acid washing)  (A) and de- 
graded ligand (trichloroacetic acid-soluble radioactivity in the su- 
pernatant) (B) were determined as described in the Materials and 
Methods section, and expressed as a percent of total radioactivity 
bound at 4°C. Nonspecific binding was determined in the pres- 
ence of 200 nM pro-uPA and substracted. Specifically  bound ra- 
dioactivity at 4°C was 2.6 fmol/well (2.4 and 2.8 in the two experi- 
ments). Data are the average of two experiments in duplicate. 
step of binding to uPAR, a second step which must include 
the interaction of uPAR-bound uPA-serpin with the LRP/ 
et2-MR,  and a  third  step  leading  to internalization  of the 
complexes. 
uPA-PAI- l-dependent Internalization of 
uPAR in U937 and LB6 Clone 19 Cells. Requirement 
for LRP/a2-MR 
We have  tested  whether  the  internalization  of the  uPA- 
serpin complexes is accompanied by the internalization of 
uPAR. If uPAR is internalized,  its expression on the cell 
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tion of uPA-PAI-1 or uPA-PN-1. Therefore, the presence 
of uPAR on the cell surface of human U937 cells was stud- 
ied by FACS analysis using anti-uPAR monoclonal anti- 
bodies that can be followed by cytofluorimetry with a fluo- 
rescent anti-mouse antibody. As shown in Fig. 3 A, specific 
uPAR  fluorescence  was  measured  with  antibody  R2  on 
U937 ceils incubated  at 4°C for 120 min with 1 nM uPA- 
PAI-1 or free uPA. In control experiments  (not shown), it 
was established that binding of uPA, uPA-PAI-1, or uPA- 
PN-1  did not interfere  with  the  recognition  of uPAR by 
the  antibody  R2  by  the  cytofluorimetric  technique,  in 
agreement  with  the  domain  specificity  of  this  antibody 
(RCnne et  al.,  1991).  The same level of fluorescence was 
measured  when cells  were  incubated  with  uPA or uPA- 
PAI-1 (Fig. 3 A). When the cells were allowed to incubate 
for additional  30 min at 37°C, a  decrease in fluorescence 
was observed with uPA-PAI-1, as evidenced by a leftward 
shift  in  the  mean  fluorescence  peak,  but  not  with  uPA 
(Fig.  3  A).  A  similar  downregulation  was observed with 
uPA-PN-1 complexes (not shown). To test whether the re- 
duction in uPAR-specific fluorescence was really correlated 
to uPA-PAI-1 or uPA-PN-1 internalization,  we repeated 
the experiment  testing also the effect of the LRP/ct2-MR 
ligand RAP. As shown in Fig. 3 B, the decrease in uPAR- 
fluorescence observed after incubation of U937 cells with 
both uPA-PAI-1 and uPA-PN-1 at 37°C was prevented by 
the presence of RAP. These results therefore show that in 
U937 cells a  downregulation of cell-surface uPAR occurs 
during uPA-PAI-1 and uPA-PN-1 internalization, and sug- 
gest that this process may require LRP/o~2-MR. 
To better examine internalization of uPAR, we used con- 
focal epifluorescence microscopy. LB6 clone 19 cells were 
incubated  with  uPA  or  uPA-PAI-1 for  120  min  at  4°C, 
washed and incubated  at 37°C in the absence of ligand for 
an additional 30 min. At the end of the 4  ° or 37°C incuba- 
tion, the cells were permeabilized,  fixed, and stained with 
the  anti-uPAR  mAb  R2  (see  Materials  and  Methods). 
Upon  incubation  at  4°C  with  either  uPA  (Fig.  4  a)  or 
uPA-PAI-1,  (Fig.  4,  b-d),  staining  of uPAR was visible 
largely at  the periphery of the cells, most strongly at  the 
cell  contours.  Treatment  of the  cells  with  cycloheximide 
before  the  incubation  with  uPA  or  uPA-PAI-1  did  not 
drastically change this picture. 
We  next  followed  uPAR  immunofluorescence  during 
uPA-PAI-1 internalization, i.e., analyzing cells after a shift 
to 37°C for 30 min, a time providing maximal intracellular 
enrichment  of uPA-PAI-1 (see f.e., Fig.  1).  As shown in 
Fig. 4, e-g, under these conditions uPAR was detected in- 
side the cells, largely in the perinuclear region. Perinuclear 
location was not exclusive, however, since staining was still 
observed at the periphery. The results suggest that uPAR 
was at least in part internalized in uPA-PAI-l-challenged 
LB6 clone 19 cells during the 37°C incubation.  Similar re- 
suits were obtained with the uPA-PN-1 complex, whereas 
no perinuclear  staining was observed with free uPA  (data 
not shown). The persistence of cell surface uPAR under the 
internalization  conditions  is explained  by the use of non- 
saturating  conditions  of ligands  (1  nM).  Importantly,  the 
presence  of the  LRP/et2-MR ligand  RAP throughout  the 
experiment totally prevented the intracellular localization 
(Fig. 4 h). These results overall strongly suggest that in the 
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Figure 3. Cytofluorimetric analysis of uPAR downregulation dur- 
ing  uPA-PAI-1  and  uPA-PN-1  internalization  in  U937  cells: 
LRP/otE-MR dependence.  In all  graphs, the  abscissae  show the 
mean fluorescence intensity (log scale),  while  the ordinates rep- 
resent the channel number (linear scale), i.e., the number of cells. 
(A)  The left panels (a and b) refers to cells challenged with uPA- 
PAI-1, the right panels (c and d) to cells challenged with uPA (1 
nM in both cases).  Control peak in a refers to cells treated only 
with the fluorescein-conjugated antibody. Monoclonal anti-uPAR 
antibody R2 was used for the analysis.  Shown in a  and c is the 
cytofluorimetric analysis of cells incubated only at 4°C; in b and d 
the cells were incubated with the ligand at 4°C for 120 min, and 
then exposed to 37°C for 30 min. (B) The cells were incubated with 
1 nM uPA-PAI-1 (a, b, and c) or uPA-PN-1 (d, e, and f) for 120 
min at 4°C  in the absence (a, b, d, and e) or in the presence of 200 
nM RAP (c and]), and then either maintained at 4°C (a and d) or 
incubated for 30 min at 37°C in the absence (b and e) or in the 
presence of 200 nM RAP (c and f). Control peak in panel a refers 
to cells treated only with the fluorescein-conjugated antibody. 
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that internalization requires LRP/a2-MR. 
In a  separate  experiment carried out  under  the  same 
conditions, the specific  immunofluorescence of LB6 clone 
19 cells challenged with uPA-PAI-1 at 4°C was analyzed 
at different planes of focus from apical to basal (confocal 
sectioning), and the image of a  sagittal section computer- 
reconstructed from  optical sections of 0.29  txm  thickness 
(data not shown). The data of the different sections were 
saved  and  processed  to  reconstruct  a  sagittal projection 
which showed that the interior of the cell was mostly de- 
void of specific staining with the strongest staining present 
at  the  cell contours.  When,  however,  the  sagittal section 
was  reconstructed  from  cells exposed  to  uPA-PAI-1  at 
4°C for 2 h, but then chased at 37  ° for 30 rain, the interior 
of the cell was now clearly strongly positive for uPAi~ (not 
shown). 
Immunofluorescence of LB6 clone 19 cells shows a slight, 
but visible background (see Fig. 4). This background could 
interfere with the interpretation of the data since the peri- 
nuclear location might  also indicate the  presence  of bio- 
synthetic uPAR. The internalization experiment perform- 
ing under conditions in which protein synthesis is blocked 
should result in the inhibition of that  part of the perinu- 
clear staining due to biosynthetic uPAR. We first studied 
the  effect  of  cycloheximide  on  uPA-PAI-1  uptake  and 
Figure 4. Confocal immunofluorescence study of uPAR internal- 
ization in uPA-PAI-1 challenged LB6 clone 19 cells.  Untreated 
or cycloheximide (20  ixg/ml, 30 min) treated LB6 clone 19 cells 
were incubated with uPA  or uPA-PAI-1 under various condi- 
tions, and  then probed with  15  Ixg/ml R2 anti-uPAR antibody 
followed by a 1:200 dilution of rhodamine-conjugated secondary 
anti-mouse antibody (see Materials and Methods). When present, 
cycloheximide was present throughout the experiment. Negative 
control  included  the  omission  of  the  specific  antibody  and 
showed no staining. (a) Incubation with 1 nM uPA for 120 min at 
4°C; (b and c) Incubation with l  nM uPA-PAI-1 for 120 min at 
4°C in the presence of cycloheximide; (d) incubation with 1 nM 
uPA-PAI-1,120 min at 4°C; (e and f) incubation with 1 nM uPA- 
PAId, 120 min at 4°C, and then chased for 30 min at 37°C; (g) in- 
cubation with  1  nM  uPA-PAI-1 in  the  presence of cyclohexi- 
mide, 120 min at 4°C, and then 30 min chase at 37°C; (h) incuba- 
tion with 1 nM uPA-PAI-1,120 min at 4°C, and then 30 min at 37°C, 
in the presence of cycloheximide and 200 nM RAP. Bar, 15 0.m. 
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Figure 5.  Effect of cycloheximide on the internalization and deg- 
radation of uPA-PAI-1. LB6 clone 19 cells (0.2  ×  106/well) were 
incubated with  100,000 cpm  i25I-uPA-PAI-1 (1  nM,  7.7  x  103 
cpm/ng) on ice for 120 min, washed, and then warmed up to 37°C 
for 0, 30, and 120 min. Acid washed ligand (circles),  cell-associ- 
ated (i.e., remaining radioactivity after acid washing) (squares) 
and trichloroacetic acid-soluble ligand in the supernatant (trian- 
gles) were determined (see Materials and Methods) and the val- 
ues expressed in percent of bound radioactivity. When present 
(closed symbols) cycloheximide (20 I~g/ml) was added 30 min be- 
fore the  binding step and  remained in  the  incubation mixture 
throughout the experiment. Nonspecific binding was determined 
by competition with 100 nM pro-uPA and substracted. Bound ra- 
dioactivity at 4°C was 18.7 and 19.4 fmol/well in the absence or in 
the presence of cycloheximide, respectively. The amount of de- 
graded uPA-PAI-1 complexes did not change in the presence of 
cycloheximide (14.4  vs 11.9 fmol in control and cycloheximide- 
treated cells, respectively). Results are the average of two inde- 
pendent experiments in duplicate (less than 10% variation). 
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clone  19 cells is surface  exposed.  LB6 clone  19 cells (0.2 ×  106/ 
well) were incubated in the absence or in the presence of PI-PLC 
(10 U/ml) for 15 min at 37°C, washed and lysed in 1% Triton 
X-100 lysis buffer (see Materials  and Methods).  Supernatants (S) 
and  extracts (L) were assayed  for solubilized  uPAR by cross- 
linking to 125I-ATF  and analyzed by SDS-PAGE and autoradiog- 
raphy (see Materials  and Methods section).  The conjugate  1251- 
ATF-uPAR and free 125I-ATF  migrate with an apparent mobility 
of around 70 kD and 15 kD, respectively. Free 125I-ATF  has run 
out of the gel. The migration of molecular weight  standards  is 
shown on the left. 
degradation.  As shown in  Fig.  5,  the  treatment with the 
protein synthesis inhibitor before and during the incuba- 
tion at 37°C with uPA-PAI-1, did not affect the uptake pa- 
rameters: neither the level of acid-wash resistant radioac- 
tivity  nor  the  extent  of  degradation  of  the  uPA-PAI-1 
complex. At the concentration used (20 txg/mL) cyclohex- 
imide inhibited protein synthesis by more than 99%  (not 
shown). When the confocal experiment of Fig. 4 was per- 
formed in the presence of cycloheximide, the perinuclear 
location of uPAR after the 37  ° incubation was not affected 
(Fig.  4,  e  and  f').  Cycloheximide  had  also  no  effect  on 
uPAR distribution at 4  ° (Fig. 4, b and c). Thus, the perinu- 
clear staining was not due to de novo synthesized uPAR. 
In conclusion, cycloheximide affected neither uPA-PAI-1 
internalization  and degradation (Fig. 5) nor the immuno- 
localization of uPAR while RAP inhibited uPA-PAI-1 in- 
ternalization  and  degradation  (see Fig.  2)  as  well as the 
perinuclear translocation of uPAR (Fig. 4 g). These results 
thus  further  support  the  conclusion  that  the  perinuclear 
uPAR  represents internalized  uPAR  and  that  this  inter- 
nalization requires LRP/a2-MR. 
To eliminate the possibility of the presence of a signifi- 
cant  intracellular  pool of uPAR,  we performed an addi- 
tional  experiment  testing  in  the  absence  of  any  ligand 
whether all of the ATF-binding uPAR was exposed on the 
cell surface in LB6 clone 19 cells.  Cells were treated  (or 
not) with PI-PLC and subsequently both the supernatant 
and the extract were assayed for uPAR by 125I-ATF cross- 
linking.  It is known that under these conditions,  cell sur- 
face uPAR is released into the supernatant, whereas any 
uPAR not present on the cell surface remains in the cell 
pellet (MOiler et al., 1993). Moreover, any immature, bio- 
synthetic uPAR displays a faster migration on gel and can 
be distinguished from the mature, cell surface form as be- 
ing completely glycosylated and cell surface exposed (Beh- 
rendt et al., 1990; Moiler et al., 1992). As shown in Fig. 6, 
in the absence of the PI-PLC treatment, most (over 95% 
as judged by film scanning)  of uPAR was present in the 
cell lysate, as shown by the presence of the ~70 kD 1251- 
ATF-uPAR conjugate, whereas after a treatment with PI- 
PLC, all of it was present in the  supernatant.  Moreover, 
the migration of the ATF-uPAR adduct was identical in 
the  two conditions.  This experiment shows therefore the 
absence of any major intracellular  pool of uPAR  within 
LB6 clone 19 cells. 
Internalization of uPAR was also followed by electron 
microscopy of cryosections prepared for immunocytochem- 
istry, using LB6 clone 19 cells incubated and prepared as 
described in the Materials and Methods section. After in- 
cubation  for 2  h  at  0°C  with  100  nM  uPA-PAI-1,  77% 
uPAR was found located on the plasma membrane includ- 
ing microvilli, whereas only 23 % was found in intracellular 
vacuoles (Fig.  7, A  and B  and Table I).  However, after 
further chase incubation at 37  ° for 30 min, the labeling of 
the plasma membrane decreased from 77 to 7%  and the 
intracellular  vacuolar  labeling  increased  from 23  to  93% 
mainly along the endosomal membrane (Fig. 8, A-D  and 
Table I). Identical results were obtained with affinity-puri- 
fied polyclonal as well as monoclonal anti-uPAR antibod- 
ies. Internalization was totally abolished if the cells were 
incubated under the same conditions but with the addition 
of 400 nM  RAP  (Fig.  9 A  and Table I). Likewise, there 
was no internalization of uPAR if the cells were incubated 
under the same conditions but using DFP-uPA instead of 
uPA-PAI-1 (Fig. 9 B and Table I). In conclusion, we show 
that plasma membrane uPAR can be translocated into in- 
tracellular endosome-like particles, but this process is spe- 
cific for uPA-PAI-1, occurs only at 37°C and is inhibited 
by the LRP/et2MR agonist RAP. 
Discussion 
The receptor for uPA has the peculiar property of induc- 
ing  the  internalization  of some  (uPA-serpin  complexes) 
but not other ligands (uPA, pro-uPA, DFP-uPA, ATF) (Cu- 
bellis et al.,  1990).  This property is acquired because the 
serpin  moiety can  interact with  the  LRP/a2-MR or  other 
members of the LDL receptor gene family (Nykjaer et al., 
1992; Herz et al., 1992; Moestrup et al., 1993a;  Kounnas et 
al.,  1993; Li et al.,  1994).  Previous studies have shown that 
uPAR binding represents the first and essential step for an 
efficient degradation of uPA-serpin complexes in human 
U937 cells and in murine LB6 clone 19 cells (Olson et al., 
1992; Conese et al., 1994). Indeed, at physiological concen- 
trations, only serpin complexes with uPA derivatives con- 
taining  the  uPAR-binding  region  (i.e.,  solely  two-chain 
uPA) can be degraded, while those missing the growth fac- 
tor domain (33 kD, low molecular weight-uPA, 33-kD-uPA- 
PAI-1 or 33-kD-uPA-PN-1 complexes) cannot (Vassalli et 
al., 1985;  Stoppelli et al., 1985,  1986;  Cubellis et al., 1986, 
1990; Jensen et al., 1990; Olson et al., 1992;  Conese et al., 
1994).  Moreover, complexes of the same serpin with other 
Conese et al. uPA Receptor Internalization  1615 Figure 7.  Immuno-electron microscopy analysis of uPAR internalization in LB6 clone 19 cells: incubation with uPA-PAI-1 at 0°C. Elec- 
tron micrographs from cryosections of LB6 clone 19 cells were prepared for immunocytochemistry as described in the Materials and 
Methods section. The cells were incubated with 100 nM uPA-PAI-1 for 3 h at 0°C, washed, and fixed.  (A) Polyclonal rabbit affinity- 
purified anti-uPAR antibodies. (B) Mouse monoclonal anti-uPAR antibody R2. Labeling is seen on the plasma membrane including 
microvilli (arrows). Endosomes (EN) show very little labeling.  Bars, 0.25 ixm. 
proteases  (like  the  thrombin:PN-1  complex)  fail  to com- 
pete for uPA-PN-1 degradation  (Conese et al.,  1994). Fi- 
nally,  prevention  of binding  to  uPAR by specific uPAR 
antibodies,  nondegradable  uPA  derivatives  (like  ATF, 
DFP-uPA) or by treatment of cells with the uPAR-releas- 
ing PI-PLC, prevents  internalization  and  degradation  of 
uPA-serpin complexes  (Olson et  al.,  1992;  Conese  et  al., 
1994). 
On  the  other  hand,  the  LRP/etz-MR  ligand  RAP  and 
LRP/o~2-MR antibodies, while incapable of preventing cell 
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uPA-serpin complexes (Nykj~er et al., 1992; Conese et al., 
1994). Since uPA-serpins can bind LRP/t~2-MR (Fig. 1), as 
already shown previously (Kounnas et al., 1993; Nykj~er et 
al., 1992, 1994a; Conese et al., 1994), we believe that bind- 
ing initially to uPAR and subsequently to LRP/et2-MR are 
prerequisites for internalization and degradation. Because 
of their affinity for  LRP/et2-MR, high concentrations of 
uPA-serpin  complexes may still  be  taken  up  in  uPAR- 
lacking cells, and in this case the uptake is enhanced by the 
transfection of uPAR cDNA (Li et al., 1994). 
Uptake of the uPA-PAI-1 complex into lysosomes (Jen- 
sen et al., 1990; Olson et al., 1992) is followed by its degra- 
dation (Cubellis et al.,  1990). The mechanism underlying 
uPA-serpin internalization and the respective functions of 
uPAR and LRP/e~2-MR  are issues that are not yet clear. 
With cells containing both receptors and when the ligands 
are used at physiological concentrations, uPAR is clearly 
the binding site, in agreement with the measured affinities 
of uPA-PAI-1 for uPAR and LRP/et2-MR (Cubellis et al., 
1989; Nykj~er et al., 1994). At higher concentrations, LRP/ 
%-MR might directly bind to and hence internalize uPA- 
serpins  even in  the  absence  of uPAR  (Kounnas  et  al., 
1993; Nykj~er et al., 1994a). 
Downregulation of uPAR during uPA-PAI-1  internal- 
ization has been suggested previously (Olson et al.,  1992; 
Li et al., 1994). We now demonstrate that downregulation 
coincides with the internalization of uPAR  (Figs. 3, 4, 5, 
and 7-9). Moreover, both uPAR downregulation in cytoflu- 
orimetry (Fig. 3) and internalization by confocal immuno- 
fluorescence and immunoelectron microscopy experiments 
(Figs. 4, 7-9) are LRP/aE-MR-dependent, as demonstrated 
by the inhibitory effect of RAP. The confocal data suggest 
a translocation of uPAR from the pericellular to a perinu- 
clear position only when cells have been exposed to the 
uPA-serpin complex and after they have been incubated 
at 37°C. Computer reconstruction images do show that un- 
der those conditions the interior of the cell is filled with 
uPAR (not shown). 
The immunoelectron microscopy experiments of Figs. 
7-9, carried out under conditions in which uPAR was satu- 
rated  by  the  ligand,  demonstrate  the  internalization  of 
uPAR. When cells were analyzed in the absence of ligands 
(not shown) or in the presence of uPA-PAI-1 at 0°C (Fig. 
7, A and B), uPAR was observed exclusively at the cell sur- 
face or on microvilli, in agreement with the internalization 
specificity for the uPA-se~pin complexes. In particular, en- 
dosome-like structures were largely deprived of specific la- 
beling. When, however, cells exposed to uPA-PAI-1 com- 
plex were further chased at 37°C, uPAR was also found in 
vacuolar, endosome-like structures (Fig. 8, A-D). The pres- 
ence of intracellular uPAR was no longer observed when 
the incubation mixture also contained the LRP/a2MR ago- 
nist, RAP (Fig. 9 A).The internalization of uPAR was spe- 
cific for the uPA-PAI-1  complex; in fact, with DFP-uPA 
at  37°C  (Fig.  9  B),  the  electron microscopy experiment 
gave results identical to those observed with uPA-PAI-1 
only incubated at 0°C. That the vacuolar structures did not 
represent invaginations of the plasma membrane is strongly 
suggested by the very appearance of the vesicles and by 
the following evidence: (a) LB6 clone 19 cells, as opposed 
to other cells (i.e., human monocytes), have a quite regular 
surface with no deep invaginations (data not shown). (b) 
The size of the vesicle was ~0.7 Ixm in diameter, and the 
distance from the plasma membrane often ,--,2.5 txm. 
The quantitative analysis of the electron microscopy ex- 
periments unequivocally demonstrates the internalization 
of uPAR. In fact (Table I),  uPAR translocation from the 
plasma membrane to intracellular vacuoles appeared to be 
quantitative (over 90%), specific (not observed with DFP- 
uPA),  and dependent on the LRP/et2MR agonist  (inhib- 
ited by RAP). 
That intracellular uPAR does not represent biosynthetic 
uPAR nor an intracellular pool of uPAR is shown by the 
lack of effect of the protein synthesis inhibitor cyclohexi- 
mide (as tested in uPA-PAI-1 degradation and in uPAR 
confocal microscopy experiments) and by the lack of an 
intracellular pool of uPAR in the absence of ligands,  as 
studied by cross-linking experiments (Figs.  4-6).  On  the 
other hand, the dependence of uPAR downregulation by 
the  LRP/e~2-MR  was confirmed also in the cytofluorime- 
try  and  confocal  and  electron  microscopy  experiments 
(Figs. 3, 4, and 9). 
On the basis of the results presented in this paper, we 
conclude that during the process of the internalization of 
the uPA-serpins, uPAR itself is internalized. This process 
is tied up with that of LRP/ctE-MR, but we do not know 
whether a tripartite uPAR/uPA-serpin/LRP/ctE-MR com- 
plex is internalized as a whole, or through different path- 
ways. The situation is complicated by the fact that uPAR is 
GPI-anchored and might therefore also be located in ar- 
eas, like caveolae, distinct from those accessible to LRP/ 
et2-MR. However, a recombinant uPAR molecule anchored 
via a transmembrane region internalizes uPA-PAI-1 com- 
plexes as efficiently as the GPI-anchored uPAR in LRP/ 
ct2-MR-expressing cells (Li et al.,  1994; M¢ller, L. B., and 
F. Blasi, unpublished results). 
The results presented in this paper demonstrate there- 
fore that the process of uPA-PAI-1 internalization is com- 
plex. Such a mechanism must be common to the internal- 
ization of both uPA-PAI-1 and uPA-PN-1 as the kinetics 
and  the  dependence on LRP/%-MR  are  the  same.  The 
fate of uPAR after internalization remains an open ques- 
tion. One possibility is that it may be delivered to the lyso- 
somes and degraded. Alternatively, uPAR might be recy- 
Table I. Distribution of uPAR on LB6 Clone 19 Cells As 
Determined by Electron Microscope Immunocytochemistry 
uPA-PAI-  1'  uPA-PAI-  1'  uPA-PAI-  I/RAP*  DFP-uPA ~ 
0 min  30 min  30 min  30 min 
%  %  %  % 
Plasma  76.9  7.0  79.7  82.4 
membrane 
Cytoplasmin  23.1  93.0  20.3  17.6 
vacuoles 
Total number of  1,540  840  2,149  3,620 
gold particles 
counted 
*Grain counting  is outlined  in detail in the Materials  and Methods  section. The data 
are shown as % of total grains, and the number of grains counted is shown in the last 
row of each column. 
*These columns indicate the four incubation conditions  outlined in detail in the Mate- 
rials and Methods section. In particular,  here they denote the ligand and effector with 
which the cells were incubated at 0°(2, and the time of chase at 37°C. 
Conese et al. uPA Receptor Internalization  1617 The Journal of Cell Biology, Volume 131, 1995  1618 Figure 8. Immuno-electron microscopy analysis of uPAR internalization in LB6 clone 19 cells: incubation with uPA-PAI-1 at 0°C with 
further chase at 37°C. Cells were incubated with uPA-PAI-1 as in Fig. 7 A, and then chased for 30 min at 37°C. (A-C) Potyclonal rabbit 
affinity purified anti-uPAR antibody. (D) Mouse monoclonal antibody R2. Only little labeling is left on the plasma membrane (arrows); 
however, significant  labeling is seen in endosomes (EN), mainly along the endosomal membrane (arrowheads) but occasionally also 
over electron-dense material in cytoplasmic vacuoles (V).  In D, the use of the monoclonal antibody gives results identical to the poly- 
clonal antibody, demonstrating labeling of the membrane of an endosome (EN) located deep in the cytoplasm and only a few gold par- 
ticles on the plasma membrane. Bars, 0.25 ~m. 
cled back to the cell surface. Recycling of uPAR would be 
consistent with a mechanism stimulating extracellular pro- 
teolysis and cell migration by continuously modifying the 
geographic location of the surface areas capable of binding 
active  uPA,  focally forming plasmin  and  hence  cleaving 
proteins at cell-matrix or cell-cell contacts. These continu- 
ous modifications would be triggered and regulated by the 
formation of the uPA-serpin complexes, since both PAI-1 
and PN-1 are present in the extracellular matrix. In partic- 
ular,  active  PAI-1  is  directly bound  by the  extracellular 
matrix  protein vitronectin  (Salonen  et  al.,  1989).  The re- 
cent report that uPAR can bind, in addition to uPA, also 
vitronectin (Wei et al., 1994), would be in agreement with 
the  above  hypothesis,  as  the  binding  of  vitronectin  to 
uPAR would allow direct regulation  of cell surface  uPA 
activity. This  hypothesis would  also explain  the  apparent 
paradox that increase in PAI-1 is associated with a higher 
metastatic risk in human cancer (Grcndahl-Hansen  et al., 
1993).  We  are  currently  investigating  whether  uPAR  in 
fact undergoes recycling after internalization. 
Conese et al. uPA Receptor Internalization  1619 Figure 9. Immuno-electron microscopy analysis of uPAR internalization in LB6 clone 19 cells: dependence on LRP/ct2MR and specific- 
ity for uPA-PAI-1. (A) Cells were incubated as in Fig. 8, but with the addition of 400 nM RAP. (B) Cells were preincubated for 2 h with 
100 nM DFP-uPA at 0°C, and then chased for 30 min at 37°C. In both cases the antibody was rabbit anti-uPAR serum, affinity-purified. 
(A)In these cells the plasma membrane is heavily labeled including the microvilli (arrows) and only occasional labeling of endosomes is 
seen (arrowheads), showing the requirement for LRP/tx2MR. (B) Again, the plasma membrane and the microvilli are heavily labeled 
and only little endosomal labeling is seen (EN, arrowheads), in agreement with the deficient internalization of DFP-uPA. Bars, 0.25  ixm. 
The Journal of Cell Biology, Volume 131, 1995  1620 The  internalization  process  might  also  be  connected 
with uPAR-mediated signal  transduction.  Indeed, in  the 
presence of a chemotactic gradient, uPAR has been shown 
to cluster at the leading edge of monocytic cells (Eistre- 
cher et  al.,  1990;  Gyetko et al.,  1994).  Moreover, it has 
been shown that several protein molecules, including non- 
receptor tyrosine kinases  and  integrins,  are present in  a 
macromolecular complex containing uPAR  (Bohuslav et 
al.,  1995).  However, we  have  no information as  to  how 
these findings relate to known functions of uPAR, nor to 
its LRP/a2MR-mediated internalization. Additional work 
is needed to clarify all these points. 
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